He declines to say when, if ever, his company will be cash-flow positive but says he has more than enough to attain that distinction. BlueArc employs 160. Develops therapeutics for treating cancer. Suicide is seldom seen as a noble act, but if each cell in your body didn't commit the deed when the time was right, humans would be riddled with cancer and other diseases. Gemin X Biotechnologies develops drugs that ensure cells can do themselves in.
All cells have a self-destruct program, called apoptosis.
It comes into effect at the end of a cell's useful life or after it incurs irreparable damage. If cells are unable to commit suicide, cancerous cells and tumors form. In many forms of cancer, a protein called Bcl-2 blocks apoptosis. The protein jams up the molecular pathway that enables cells to commit suicide. CEO Dan Giampuzzi says the drug may be effective in treating B-cell lymphoma and breast, lung, prostate, and colorectal cancers.